Clinical Trials

    A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)

    Investigator: Juan Toledo Atucha

    Study Coordinator: Reena Boradia

    Status: Enrolling

    ClinicalTrials.gov Number: NCT04437511

    Phone: 713.441.1150

    Protocol Number: PRO00025839

    Description


    The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer's disease. Additional participants will be enrolled to an addendum safety cohort. The participants will be administered open-label donanemab.